Chowdhury Pallabita, Ghosh Upasana, Samanta Kamalika, Jaggi Meena, Chauhan Subhash C, Yallapu Murali M
Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, USA.
Department of Biomedical Engineering, School of Engineering, Rutgers University, The State University of New Jersey, Piscataway, NJ, 08854, USA.
Bioact Mater. 2021 Mar 13;6(10):3269-3287. doi: 10.1016/j.bioactmat.2021.02.037. eCollection 2021 Oct.
The management of aggressive breast cancer, particularly, triple negative breast cancer (TNBC) remains a formidable challenge, despite treatment advancement. Although newer therapies such as atezolizumab, olaparib, and sacituzumab can tackle the breast cancer prognosis and/or progression, but achieved limited survival benefit(s). The current research efforts are aimed to develop and implement strategies for improved bioavailability, targetability, reduce systemic toxicity, and enhance therapeutic outcome of FDA-approved treatment regimen. This review presents various nanoparticle technology mediated delivery of chemotherapeutic agent(s) for breast cancer treatment. This article also documents novel strategies to employ cellular and cell membrane cloaked (biomimetic) nanoparticles for effective clinical translation. These technologies offer a safe and active targeting nanomedicine for effective management of breast cancer, especially TNBC.
尽管治疗取得了进展，但侵袭性乳腺癌，尤其是三阴性乳腺癌（TNBC）的管理仍然是一项艰巨的挑战。虽然阿替利珠单抗、奥拉帕利和赛托珠单抗等新型疗法可以应对乳腺癌的预后和/或进展，但生存获益有限。目前的研究工作旨在开发和实施策略，以提高生物利用度、靶向性、降低全身毒性，并增强FDA批准的治疗方案的治疗效果。本综述介绍了用于乳腺癌治疗的各种纳米颗粒技术介导的化疗药物递送。本文还记录了采用细胞和细胞膜包裹（仿生）纳米颗粒进行有效临床转化的新策略。这些技术为乳腺癌，尤其是TNBC的有效管理提供了一种安全且具有主动靶向性的纳米药物。
